According to our (Global Info Research) latest study, the global Fecal Immunochemical Diagnostic Tests market size was valued at US$ 1236 million in 2025 and is forecast to a readjusted size of US$ 2260 million by 2032 with a CAGR of 9.0% during review period.
Fecal immunochemical diagnostic testing is a non-invasive diagnostic method based on the principle of antigen antibody specific reaction, which screens for lower gastrointestinal bleeding by detecting trace amounts of human hemoglobin in fecal samples. This test uses specific antibodies against human hemoglobin, which can accurately identify and measure the hemoglobin content in feces. The results are usually reported quantitatively or qualitatively in micrograms (μ g/g) per gram of feces. Compared to traditional guaiacol based fecal occult blood testing, fecal immunochemical diagnostic testing has significant advantages: it does not require dietary restrictions (avoiding red meat or certain vegetables) or discontinuation of medication (such as vitamin C), as it specifically targets human hemoglobin and avoids peroxidase interference in food, thereby significantly reducing false positive rates. The positive threshold for this test is usually set at 10 μ g/g or 20 μ g/g, with higher values indicating greater bleeding and an increased risk of intestinal lesions such as colorectal cancer. Due to its ease of operation, rapid detection, high patient compliance, and better sensitivity and specificity, fecal immunochemical diagnostic testing has become the preferred method for large-scale screening of colorectal cancer worldwide, especially suitable for annual or biennial routine screening of the average risk population.
The industry chain of fecal immunochemical diagnostic testing covers upstream suppliers of core biological materials and fine consumables such as antigen antibody raw materials and nitrocellulose membranes, midstream manufacturers of reagent kits, analyzers, and supporting consumables (such as sampling tubes and fecal sampling sticks), as well as downstream application terminals such as hospital laboratories, physical examination centers, third-party medical laboratories, and home self testing. Regarding gross profit margin, the midstream of the industrial chain exhibits significant differentiation characteristics of "high barriers and high gross profit": self owned brand manufacturers with core raw material self-produced capabilities and highly automated instrument platforms, relying on technological premiums and scale advantages, generally have high gross profit margins. Referring to similar projects in the in vitro diagnostic industry, the gross profit margin of high-tech threshold reagents such as chemiluminescence can reach over 90%, and the comprehensive gross profit margin of self owned products is about 70%; However, circulation enterprises or pure OEM manufacturers that mainly rely on agency sales have relatively low gross profit margins, usually around 40%, due to the need to offer discounts to brand owners.
The fecal immunochemical diagnostic test has been upgraded from a traditional qualitative screening "suggestive tool" to a "group defense line" in the global colorectal cancer prevention and control system that combines high compliance and high health economic value. Its revolutionary breakthrough lies in abandoning the strict restrictions of chemical methods on diet and medication, and accurately capturing trace amounts of gastrointestinal bleeding through specific anti human hemoglobin antibodies, thereby significantly improving the detection rate of early precancerous lesions (advanced adenomas) while significantly reducing the burden of unnecessary colonoscopy caused by false positives. It is not only the current optimal large-scale screening solution that balances "sensitivity, specificity, cost, and convenience", but also a key pivot to promote colorectal cancer screening from "passive diagnosis" to "active prevention" - by establishing a positive threshold of 10 μ g/g stool, the disease prevention checkpoint is moved forward to the precancerous lesion stage, truly realizing the modern medical concept of "screening is prevention". The degree of promotion and popularization has directly become a core indicator for measuring the level of early diagnosis and treatment of colorectal cancer in a country.
This report is a detailed and comprehensive analysis for global Fecal Immunochemical Diagnostic Tests market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Fecal Immunochemical Diagnostic Tests market size and forecasts, in consumption value ($ Million), 2021-2032
Global Fecal Immunochemical Diagnostic Tests market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Fecal Immunochemical Diagnostic Tests market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Fecal Immunochemical Diagnostic Tests market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Fecal Immunochemical Diagnostic Tests
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Fecal Immunochemical Diagnostic Tests market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eiken Chemical, Kyowa Medex, Alfresa Pharma Corporation, Sysmex Corporation, Fujirebio, Sentinel Diagnostics, R-Biopharm AG, Polymedco, Thermo Fisher Scientific, BioMerieux, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Fecal Immunochemical Diagnostic Tests market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
High Sensitivity:>90%
Moderate Sensitivity: 70% -90%
Lower Sensitivity:<70%
Market segment by Data Parameters
Qualitative Test
Quantitative Test
Market segment by Technology Platform
Immunoturbidimetry
Immunochromatography
Market segment by Application
Cancer Centers
Nursing Homes
Hospitals
Homecare Settings
Market segment by players, this report covers
Eiken Chemical
Kyowa Medex
Alfresa Pharma Corporation
Sysmex Corporation
Fujirebio
Sentinel Diagnostics
R-Biopharm AG
Polymedco
Thermo Fisher Scientific
BioMerieux
BTNX
Hemosure
Beckman Coulter
Abbott Laboratories
QuidelOrtho Corporation
Roche Diagnostics
Siemens Healthineers
Innovita Biological Technology
Ave Science & Technology
Guangzhou Wondfo Biotech
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Fecal Immunochemical Diagnostic Tests product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Fecal Immunochemical Diagnostic Tests, with revenue, gross margin, and global market share of Fecal Immunochemical Diagnostic Tests from 2021 to 2026.
Chapter 3, the Fecal Immunochemical Diagnostic Tests competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Fecal Immunochemical Diagnostic Tests market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Fecal Immunochemical Diagnostic Tests.
Chapter 13, to describe Fecal Immunochemical Diagnostic Tests research findings and conclusion.
Summary:
Get latest Market Research Reports on Fecal Immunochemical Diagnostic Tests. Industry analysis & Market Report on Fecal Immunochemical Diagnostic Tests is a syndicated market report, published as Global Fecal Immunochemical Diagnostic Tests Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Fecal Immunochemical Diagnostic Tests market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.